If side effects occur, the most common are nausea, indigestion, flatulence, diarrhea, constipation, headache, and fatigue, which usually resolves within the first month of use
Medication effectiveness concerns surface in some reviews
In this context, glucagon-like peptide-2 (GLP-2) and its sister molecule glucagon-like peptide-1 (GLP-1) are of particular interest, as being critically involved in hepatic lipid homeostasis 5,6
The SELECT trial, published in the New England Journal of Medicine in 2023, showed that semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease
GLP-1RAs can cross the bloodbrain barrier and activate brain GLP-1 receptors, leading to neuroprotection by improving insulin signaling, reducing tau hyperphosphorylation, and enhancing cognitive function in diabetic and aging models